Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Despite extensive research on ulcerative colitis (UC), the mechanisms behind its pathogenesis remain incompletely elucidated. Sanhuang Shu'ai decoction (SSD) has granted attention for its potential therapeutic influences in inflammatory conditions, yet the protective mechanisms of SSD in UC models are lacking.
Methods: We investigated the protective effects of SSD extract utilizing two experimental models: lipopolysaccharide (LPS)-induced human colonic organoids and dextran sulfate sodium (DSS)-provoked murine models. In vitro and in vivo validations were conducted to ascertain the protective effects, epithelial barrier (EB) integrity, histological morphology, and inflammatory response following treatment with SSD. Moreover, mechanistic studies were applied to investigate the implication of autophagy modulation and mitophagy activation in the observed protective effects.
Results: Treatment with SSD significantly increased cell viability and EB integrity maintenance in organoids. In DSS-induced UC models, SSD treatment led to considerable improvements in tissue morphology, reduced inflammation, and restored the structural integrity of intestinal epithelial cells, thereby affirming its protective role against UC. Mechanistically, SSD was found to modulate autophagy via PIP4K2C and promote mitophagy through the wogonin-PIP4K2C-PINK1 signaling pathway.
Conclusion: SSD effectively alleviates the symptoms of UC by promoting intestinal barrier functionality and decreasing inflammatory responses. The mechanism involves wogonin promoting the interaction between PIP4K2C and PINK1 to form a Wogonin-PIP4K2C-PINK1 trimer complex, start the PINK1/Parkin signaling axis, and then promote mitochondrial autophagy and repair the intestinal EB, thus exerting the effect of treating UC. It provides a new target for UC treatment and promotes the research of Chinese medicine compounds from empirical description to precise regulation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.phymed.2025.157163 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances and prospects of ergothioneine in the treatment of cognitive frailty.
Ann Med
December 2025
School of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Background: To review the biological functions of ergothioneine (ERGO), its correlation with plasma levels in cognitive frailty, and research progress in treating frailty and cognitive impairment, with the aim of providing a reference for ERGO application in cognitive frailty treatment.
Methods: A comprehensive review of existing literature on ERGO's chemical structure, sources, antioxidant and anti-inflammatory effects, and its role in cognitive frailty was conducted. Clinical trial data and metabolomic studies were also analyzed to understand ERGO's therapeutic potential.
Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer.
Mol Diagn Ther
September 2025
Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.
Background And Objective: Sacituzumab govitecan, an anti-trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate, has been approved by both the US Food and Drug Administration and European Medicines Agency for patients with metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease. Although TROP2 evaluation is not required for patient selection, survival data from the ASCENT trial show improved response rates in patients with high TROP2 expression by immunohistochemistry. However, there is no standardized testing assay for these patients.
View Article and Find Full Text PDFEstablished and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond.
Heart Lung Circ
September 2025
Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA,
Cardiovascular-kidney-metabolic (CKM) syndrome is a term that is increasingly used to describe interconnected conditions that lead to poor health outcomes, including cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. Historically, there have been very few targeted pharmacotherapies available that have changed cardiovascular outcomes for people with CKM syndromes; however, over the past decade, new pharmacologic options have rapidly expanded, with strong evidence for cardiovascular and kidney protective benefits in CKM conditions. Of note, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have emerged as key therapeutic options and are now widely guideline-endorsed.
View Article and Find Full Text PDFStable apelin-13 analogues promote cell proliferation, differentiation and protect inflammation induced cell death.
Mol Cell Neurosci
September 2025
Biomedical and Forensic Science, School of Human Sciences, University of Derby, Derby, DE22 1GB, United Kingdom; Life and Health Sciences, University of Roehampton, London, SW15 5PH, United Kingdom. Electronic address:
Emerging evidence indicates that apelin, an adipokine, plays a critical role in numerous biological functions and may hold potential for therapeutic applications; however, its efficacy is constrained by rapid plasma degradation. Thus, the search for novel apelin analogues with reduced susceptibility to plasma degradation is ongoing. We have previously shown novel modified apelin-13 analogues, providing exciting opportunities for potential therapeutic development against Alzheimer's disease.
View Article and Find Full Text PDFSubcutaneous administration of the sphingosine kinase 2 inhibitor ABC294640 has no metabolic benefits in high fat diet-induced obesity in male mice.
Life Sci
September 2025
Department of Experimental Medical Science, Faculty of Medicine, Lund University, 221 84, Lund, Sweden; Wallenberg Center for Molecular Medicine, Faculty of Medicine, Lund University, 221 84, Lund, Sweden. Electronic address:
Aims: Experimental evidence suggests an important role for sphingosine-1-phosphate (S1P) and its generating enzymes sphingosine kinase 1/2 (SphK1/2) in obesity. We and others have shown that plasma S1P levels are elevated in obese mice and humans. Preclinical studies suggest that genetic SphK2 ablation in mice protects from age- and diet-induced obesity and metabolic dysfunction.
View Article and Find Full Text PDF